INTRODUCTION {#s1}
============

Patients with advanced esophageal cancer presenting with dysphagia often experience malnutrition as well as impairment of performance status and quality of life. Disease-related malnutrition may suppress anti-tumor immunity and is an independent predictor of worse clinical outcomes \[[@R1]\]. The geriatric nutritional risk index (GNRI) was established by Bouillanne *et al*. as a risk screening tool for nutrition-related morbidity and mortality \[[@R2]\]. The GNRI is a widely used, simple, and objective measure, calculated using the body mass index (BMI) and serum albumin levels. Serum albumin is a clinically relevant indicator of nutritional status, such as malnutrition and cachexia \[[@R3], [@R4]\]. Additionally, hypoalbuminemia is often associated with systemic inflammation and impaired host immune responses \[[@R5], [@R6]\]. Systemic inflammation promotes tumor progression and metastasis \[[@R7]\]. Concurrently, the BMI, which is calculated using body weight and height, is also used to assess the nutritional status of an individual. A low BMI is known to be a negative prognostic factor in several cancers \[[@R8], [@R9]\].

Recently, it has been widely accepted that the GNRI was strongly associated with mortality in elderly hospitalized patients and in patients with various cancers \[[@R10]--[@R12]\]. However, to the best of our knowledge, there have been few reports on the prognostic significance of the GNRI in patients with esophageal squamous cell carcinoma (ESCC). In this study, we have investigated whether the GNRI is a useful predictor of long-term survivals in patients with ESCC who underwent a curative esophagectomy.

RESULTS {#s2}
=======

Association between the GNRI and various clinicopathological features {#s2_1}
---------------------------------------------------------------------

The association between the GNRI and clinicopathological features in all patients in this study is shown in [Table 1](#T1){ref-type="table"}. Based on the GNRI cutoff value of 97.1, 81 (42.4%), and 110 (57.6%) patients were classified as having low and normal GNRIs, respectively. There was a significant association between the GNRI and various clinicopathological factors, such as the BMI (*p* \< 0.0001), tumor size (*p* \< 0.0077), depth of tumor (*p* \< 0.0001), the pathological tumor-node-metastasis (pTNM) stage (*p* = 0.0038), serum squamous cell carcinoma (SCC) antigen (*p* = 0.0001), serum albumin levels (*p* \< 0.0001), and C-reactive protein (CRP) levels (*p* \< 0.0001).

###### Relationships between GNRI and clinicopathological features in all patients with ESCC

  Characteristics                  Total patients   GNRI                                      
  -------------------------------- ---------------- -------------------- -------------------- -----------
  Age (years)                                       67 (48--84)          66 (47--85)          0.3170
  Sex                                                                                         0.1267
   Male                            169              75                   94                   
   Female                          22               6                    16                   
  BMI                                               18.5 (13.1--26.3)    22.2 (16.5--31.8)    \< 0.0001
  WBC                                               5730 (2560--12240)   5435 (2710--17140)   0.7366
   Neutrophil                                       3425 (849--9420)     3257 (860--15169)    0.5700
   Lymphocyte                                       1410 (160--3470)     1600 (380--3340)     0.0795
  Platelet                                          24.4 (8.7--49.5)     21.6 (11.2--41.8)    0.0574
  Location of tumor                                                                           0.6629
   Ce                              13               7                    6                    
   Ut                              10               4                    6                    
   Mt                              79               36                   43                   
   Lt                              69               28                   41                   
   Ae                              20               6                    14                   
  Tumor size (mm)                                   5.0 (0.2--70.0)      3.7 (0.5-48.0)       0.0077
  Depth of tumor                                                                              \< 0.0001
   T1a--1b                         81               23                   58                   
   2                               16               4                    12                   
   3                               75               39                   36                   
   4a--4b                          19               15                   4                    
  Lymph node metastasis                                                                       0.0901
   N0                              102              40                   62                   
   N1                              53               28                   25                   
   N2                              21               5                    16                   
   N3                              15               8                    7                    
  Pathological TNM stage                                                                      0.0038
   Ia--Ib                          73               20                   53                   
   IIa--IIb                        41               20                   21                   
   IIIa--IIIc                      77               41                   36                   
  Operation time (min)                              647 (156--1073)      653 (196--1258)      0.8831
  Intraoperative blood loss (ml)                    630 (0--10000)       375 (0--3000)        0.0842
  SCC antigen                                       1.3 (0.1--20.8)      0.8 (0.1--6.0)       0.0001
  Albumin                                           3.6 (2.3--4.6)       4.2 (3.3--4.9)       \< 0.0001
  CRP                                               0.20 (0.01--6.02)    0.20 (0.01--4.00)    \< 0.0001

Cox regression analysis of cancer-specific survival in all patients {#s2_2}
-------------------------------------------------------------------

Univariate analyses identified that low serum albumin levels (*p* = 0.0005), high CRP (*p* = 0.0021), low GNRI (*p* \< 0.0001), large tumor size (*p* = 0.0026), advanced pTNM stage (*p* \< 0.0001), and not being well differentiated (*p* = 0.0276) were significantly associated with worse cancer-specific survivals (CSS). Multivariate analysis revealed that the serum albumin levels (hazard ratio \[HR\], 2.498; 95% confidence interval \[CI\], 1.333--4.684; *p* = 0.0043), GNRI (HR, 1.941; 95% CI, 1.120--3.365; *p* = 0.0181), pTNM stage (HR, 3.884; 95% CI, 2.229--6.769; *p* \< 0.0001), and tumor differentiation (HR, 2.307; 95% CI, 1.262--4.220; *p* = 0.0066) were the independent prognostic factors for CSS in all patients ([Table 2](#T2){ref-type="table"}).

###### Prognostic factors for cancer-specific survival in all patients with ESCC

  Variables         Patients (*n* = 191)   Category or characteristics   Univariate analyses   Multivariate analyses                                      
  ----------------- ---------------------- ----------------------------- --------------------- ----------------------- ----------- ------- -------------- -----------
  Gender            22/169                 (female/male)                 1.310                 0.599--2.867            0.4993                             
  Age               81/110                 (\<65 / ≥65)                  0.961                 0.594--1.554            0.8713                             
  BMI               144/47                 (≥18.5 / \<18.5)              1.616                 0.946--2.758            0.0787                             
  Alb               159/32                 (≥3.5 / \<3.5)                2.747                 1.557--4.845            0.0005      2.498   1.333--4.684   0.0043
  CRP               148/43                 (\<0.5 / ≥0.5)                2.262                 1.344--3.807            0.0021      1.205   0.673--2.157   0.5300
  GNRI              110/81                 (≥97.1 / \<97.1)              2.879                 1.764--4.698            \< 0.0001   1.941   1.120--3.365   0.0181
  Tumor size        54/136                 (\<3 / ≥3)                    2.704                 1.415--5.170            0.0026      1.229   0.614--2.461   0.5600
  pTNM stage        114/77                 (I, II / III)                 4.600                 2.747--7.704            \< 0.0001   3.884   2.229--6.769   \< 0.0001
  Differentiation   64/127                 (well / other)                1.908                 1.074--3.390            0.0276      2.307   1.262--4.220   0.0066
  SCC               139/52                 (\<1.5 / ≥1.5)                1.546                 0.921--2.595            0.0990                             

The CSS and GNRI in all patients {#s2_3}
--------------------------------

In patients with low and normal GNRIs, the 3-year CSS rates were 51.3% and 79.3%, respectively, and the 5-year CSS rates were 36.9% and 73.8%, respectively. The log-rank test demonstrated that patients with low GNRIs had significantly worse prognoses, with respect to their CSS, than those with normal GNRIs (*p* = 0.0011) ([Figure 1](#F1){ref-type="fig"}). Similarly, patients with low GNRIs had a significantly worse prognosis in terms of overall survival (OS) than those with normal GNRIs (*p* \< 0.001) (Supplementary Figure 1).

![Cancer-specific survival curves in all patients with ESCC stratified by preoperative GNRI.](oncotarget-11-2834-g001){#F1}

The GNRI value relative to pTNM stage {#s2_4}
-------------------------------------

The association between the GNRI and pTNM stage is shown in [Figure 2](#F2){ref-type="fig"}. The mean preoperative GNRIs were 101.6 (range 69.8--117.0), 97.3 (range 68.8--119.1), and 96.4 (range 65.9--119.5) in patients with pTNM stage I, II, and III, respectively. There was a significant association between GNRI and pTNM stage in these patients (*p* = 0.0012).

![The GNRI values in patients with ESCC at each pTNM stage.\
On each box, the central mark indicates the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. Capped bars indicate the minimum and maximum values, respectively.](oncotarget-11-2834-g002){#F2}

Association between the GNRI and clinicopathological factors in subgroups with pTNM stage I, II, and III {#s2_5}
--------------------------------------------------------------------------------------------------------

Based on the GNRI cutoff value of 97.1, 20 (27.4%) and 53 (72.6%) patients were classified as having low and normal GNRIs, respectively. There was a significant association between the GNRI and clinicopathological factors, such as the BMI (*p* \< 0.0001), SCC antigen (*p* = 0.0019), and serum albumin levels (*p* \< 0.0001) in patients with pTNM stage I ([Table 3A](#T3A){ref-type="table"}).

###### Relationships between GNRI and clinicopathological features in patients with ESCC stage I

  Characteristics                  Total patients   GNRI                                        
  -------------------------------- ---------------- --------------------- --------------------- -----------
  Age (years)                                       70 (53--80)           66 (47--85)           0.1873
  Sex                                                                                           0.9920
   Male                            62               17                    45                    
   Female                          11               3                     8                     
  BMI                                               18.1 (13.3 -- 20.8)   22.3 (16.5--31.8)     \< 0.0001
  WBC                                               5595 (3350--10800)    5060 (2710--9940)     0.6922
   Neutrophil                                       3383 (1100--9410)     2920 (860--7296)      0.4924
   Lymphocyte                                       1470 (560--3470)      1593 (818--2600)      0.2846
  Platelet                                          23.4 (14.2 -- 35.6)   20.7 (11.2 -- 30.9)   0.0987
  Location of tumor                                                                             0.4399
   Ce                              3                1                     2                     
   Ut                              1                0                     1                     
   Mt                              32               12                    20                    
   Lt                              28               5                     23                    
   Ae                              9                2                     7                     
  Tumor size (mm)                                   3.9 (0.2--7.0)        3.7 (0.5--48.0)       0.4574
  Depth of tumor                                                                                0.8374
   T1a--1b                         61               17                    44                    
   2                               12               3                     9                     
   3                               0                0                     0                     
   4a-4b                           0                0                     0                     
  Lymph node metastasis                                                                         
   N0                              73               20                    53                    
   N1                              0                0                     0                     
   N2                              0                0                     0                     
   N3                              0                0                     0                     
  Operation time (min)                              624 (156--891)        645 (344--1217)       0.5527
  Intraoperative blood loss (ml)                    415 (50--1840)        470 (0--3000)         0.6922
  SCC antigen                                       1.1 (0.3--4.2)        0.6 (0.1--2.3)        0.0019
  Albumin                                           3.7 (3.0--4.6)        4.2 (3.6--4.9)        \< 0.0001
  CRP                                               0.20 (0.02--1.82)     0.20 (0.01--3.26)     0.9231

In patients with pTNM stage II, 20 (48.8%) and 21 (51.2%) patients were classified as having low and normal GNRIs, respectively. There was a significant association between the GNRI and various clinicopathological factors, such as the BMI (*p* = 0.0123), white blood cell (WBC) (*p* = 0.0489), neutrophil count (*p* = 0.0446), serum albumin levels (*p* \< 0.0001), and CRP (*p* = 0.0096) ([Table 3B](#T3B){ref-type="table"}).

###### Relationships between GNRI and clinicopathological features in patients with ESCC stage II

  Characteristics                  Total patients   GNRI                                      
  -------------------------------- ---------------- -------------------- -------------------- -----------
  Age (years)                                       72 (55--84)          65 (50--77)          0.0732
  Sex                                                                                         0.6740
   Male                            36               18                   18                   
   Female                          5                2                    3                    
  BMI                                               19.1 (13.1--24.4)    20.7 (17.9--27.5)    0.0123
  WBC                                               4460 (3070--11360)   6120 (3920--11340)   0.0489
   Neutrophil                                       2814 (1220--7168)    3672 (2347--8222)    0.0446
   Lymphocyte                                       1144 (160--3400)     1600 (778--3330)     0.1337
  Platelet                                          19.5 (9.4--39.7)     21.7 (13.6--41.8)    0.4416
  Location of tumor                                                                           0.6296
   Ce                              3                1                    2                    
   Ut                              6                3                    3                    
   Mt                              16               9                    7                    
   Lt                              11               6                    5                    
   Ae                              5                1                    4                    
  Tumor size (mm)                                   4.0 (2.0--8.0)       4.8 (0.5--38.0)      0.9792
  Depth of tumor                                                                              0.2220
   T1a--1b                         17               6                    11                   
   2                               3                1                    2                    
   3                               21               13                   8                    
   4a--4b                          0                0                    0                    
  Lymph node metastasis                                                                       0.1426
   N0                              21               13                   8                    
   N1                              19               7                    12                   
   N2                              1                0                    1                    
   N3                              0                0                    0                    
  Operation time (min)                              614 (270--1073)      633 (395--1258)      0.7741
  Intraoperative blood loss (ml)                    710 (0--2250)        560 (0--2620)        0.5228
  SCC antigen                                       1.1 (0.1--6.2)       0.9 (0.1--2.1)       0.3018
  Albumin                                           3.4 (2.8--4.2)       4.2 (3.6--4.9)       \< 0.0001
  CRP                                               0.33 (0.01--2.25)    0.14 (0.02--1.50)    0.0096

In patients with pTNM stage III, 41 (53.2%) and 36 (46.8%) patients were classified as having low and normal GNRIs, respectively. GNRI was significantly associated with BMI (*p* \< 0.0001), tumor size (*p* = 0.0473), depth of tumor (*p* = 0.0071), lymph node metastasis (*p* = 0.0076), intraoperative blood loss (*p* = 0.0191), serum albumin levels (*p* \< 0.0001), and CRP levels (*p* = 0.0019) ([Table 3C](#T3C){ref-type="table"}).

###### Relationships between GNRI and clinicopathological features in patients with ESCC stage III

  Characteristics                  Total patients   GNRI                                       
  -------------------------------- ---------------- -------------------- --------------------- -----------
  Age (years)                                       64 (48--84)          67 (49--84)           0.5810
  Sex                                                                                          0.0534
   Male                            71               40                   31                    
   Female                          6                1                    5                     
  BMI                                               18.5 (15.2--26.3)    22.3 (16.9--31.8)     \< 0.0001
  WBC                                               6700 (2560--12240)   5560 (3280--17140)    0.3025
   Neutrophil                                       4270 (849--9420)     3408 (2268--15169)    0.3171
   Lymphocyte                                       1480 (179--3390)     1605 (380--3340)      0.7170
  Platelet                                          25.5 (8.7--49.5)     22.5 (14.5 -- 38.0)   0.1269
  Location of tumor                                                                            0.7522
   Ce                              7                5                    2                     
   Ut                              3                1                    2                     
   Mt                              31               15                   16                    
   Lt                              30               17                   13                    
   Ae                              6                3                    3                     
  Tumor size (mm)                                   5.5 (2.0--70.0)      4.7 (1.3--32.0)       0.0473
  Depth of tumor                                                                               0.0071
   T1a--1b                         3                0                    3                     
   2                               1                0                    1                     
   3                               54               26                   28                    
   4a--4b                          19               15                   4                     
  Lymph node metastasis                                                                        0.0076
   N0                              8                7                    1                     
   N1                              34               21                   13                    
   N2                              20               5                    15                    
   N3                              15               8                    7                     
  Operation time (min)                              665 (230--986)       664 (196--1113)       0.9756
  Intraoperative blood loss (ml)                    660 (0--10000)       280 (0--1650)         0.0191
  SCC antigen                                       1.3 (0.4--20.8)      1.1 (0.1--6.0)        0.3091
  Albumin                                           3.6 (2.3--4.2)       4.2 (3.3--4.8)        \< 0.0001
  CRP                                               0.45 (0.01--6.02)    0.18 (0.02--4.00)     0.0019

Cox regression analysis of CSS depending on pTNM stage {#s2_6}
------------------------------------------------------

In patients with pTNM stage I, univariate analyses identified that low serum albumin levels (*p* = 0.0420), high CRP (*p* = 0.0153), and low GNRI (*p* = 0.0111) were significantly associated with worse CSS. Multivariate analysis revealed that CRP (HR, 7.172; 95% CI, 1.014--50.705; *p* = 0.0483) and GNRI (HR, 5.579; 95% CI, 1.191--26.133; *p* = 0.0291) were independent prognostic factors for CSS. In patients with pTNM stage II, univariate analyses confirmed that only low GNRI (*p* = 0.0095) was significantly associated with worse CSS; whereas, in patients with pTNM stage III, only low serum albumin levels (*p* = 0.0119) were significantly associated with worse CSS in the univariate analyses ([Table 4](#T4){ref-type="table"}).

###### Prognostic factors for cancer-specific survival of patients with ESCC in each pTNM stage

  Variables         Patients   Category or characteristics   Univariate analyses   Multivariate analyses                                    
  ----------------- ---------- ----------------------------- --------------------- ----------------------- -------- ------- --------------- --------
  pTNM stage I      *n* = 73                                                                                                                
  Gender            11/62      (female / male)               1.450                 0.181--11.610           0.7264                           
  Age               23/46      (\< 65 / ≥ 65)                1.358                 0.340--5.434            0.6649                           
  BMI               60/13      (≥ 18.5 / \< 18.5)            2.224                 0.460--10.760           0.3205                           
  Alb               66/7       (≥ 3.5 / \< 3.5)              5.148                 1.061--24.965           0.0420   1.267   0.148--10.854   0.8290
  CRP               67/6       (\< 0.5 / ≥ 0.5)              7.636                 1.477--39.482           0.0153   7.172   1.014--50.705   0.0483
  GNRI              53/20      (≥ 97.1 / \< 97.1)            5.537                 1.477--20.759           0.0111   5.579   1.191--26.133   0.0291
  Tumor size        54/139     (\< 3 / ≥ 3)                  0.920                 0.247--3.428            0.9010                           
  Differentiation   28/45      (well/other)                  4.455                 0.557--35.629           0.1590                           
  SCC               60/13      (\< 1.5 / ≥ 1.5)              2.436                 0.504--11.764           0.2679                           
  pTNM stage II     *n* = 41                                                                                                                
  Gender            5/36       (female / male)               0.723                 0.160--3.275            0.6742                           
  Age               18/23      (\< 65 / ≥ 65)                1.131                 0.378--3.383            0.8261                           
  BMI               30/11      (≥ 18.5 / \< 18.5)            1.399                 0.427--4.577            0.5790                           
  Alb               30/11      (≥ 3.5 / \< 3.5)              2.376                 0.767--7.360            0.1335                           
  CRP               29/12      (\< 0.5 / ≥ 0.5)              1.134                 0.348--3.693            0.8344                           
  GNRI              21/20      (≥ 97.1 / \< 97.1)            5.599                 1.525--20.566           0.0095                           
  Tumor size        54/139     (\< 3 / ≥ 3)                  2.161                 0.477--9.796            0.3179                           
  Differentiation   15/26      (well / other)                2.662                 0.731--9.691            0.1374                           
  SCC               32/9       (\< 1.5 / ≥ 1.5)              0.814                 0.180--3.678            0.7889                           
  pTNM stage III    *n* = 77                                                                                                                
  Gender            6/71       (female/male)                 1.214                 0.433--3.402            0.7122                           
  Age               36/41      (\< 65 / ≥ 65)                1.101                 0.612--1.978            0.7483                           
  BMI               54/23      (≥ 18.5 / \< 18.5)            1.096                 0.573--2.094            0.7823                           
  Alb               63/14      (≥ 3.5 / \< 3.5)              2.640                 1.239--5.626            0.0119                           
  CRP               52/25      (\< 0.5 / ≥ 0.5)              1.242                 0.665--2.321            0.4963                           
  GNRI              36/41      (≥ 97.1 / \< 97.1)            1.218                 0.677--2.193            0.5109                           
  Tumor size        54/139     (\< 3 / ≥ 3)                  1.431                 0.512--4.000            0.4950                           
  Differentiation   21/56      (well / other)                1.252                 0.632--2.478            0.5191                           
  SCC               47/30      (\< 1.5 / ≥ 1.5)              0.806                 0.441--1.473            0.4830                           

Relationship between the CSS and GNRI stratified by pTNM stage {#s2_7}
--------------------------------------------------------------

The relationship between the CSS and GNRI in each patient group stratified by pTNM stage is shown in [Figure 3](#F3){ref-type="fig"}. The 5-year CSS were significantly worse in patients with low GNRI than in those with normal GNRI, in both pTNM stage I (60.0% vs. 91.7%, *p* = 0.0044) and stage II (30.9% vs. 90.5%, *p* = 0.0036) groups. However, there was no significant difference in the 5-year CSS between patients with low and normal GNRIs (29.0% vs. 36.9%, *p* = 0.5099), respectively, in the pTNM stage III group. Similarly, patients with low GNRIs had a significantly worse OS than those with normal GNRIs (*p* \< 0.001) in pTNM stage I (*p* \< 0.0001) and stage II (*p* = 0.0020). In contrast, there was no significant association between GNRI and OS in patients with pTNM stage III (*p* = 0.1292) (Supplementary Figure 2A--2C).

![Cancer-specific survival curves in patients with ESCC at each pTNM stage stratified by preoperative GNRI (**A**) pTNM stage I (*n* = 73), (**B**) pTNM stage II (*n* = 41), (**C**) pTNM stage III (*n* = 77). Abbreviations: ESCC, esophageal squamous cell carcinoma; pTNM, pathological tumor-node-metastasis; GNRI, geriatric nutritional risk index.](oncotarget-11-2834-g003){#F3}

DISCUSSION {#s3}
==========

Many studies have identified that the tumor- or nutrition-associated factors and host immunity strongly affect the prognoses in patients with cancer \[[@R13]--[@R15]\]. Thus, this study aimed to clarify the significance of the GNRI for predicting long-term postoperative outcomes in patients with ESCC. Survival analysis in 191 patients with ESCC who received a curative esophagectomy revealed that patients with low GNRIs had significantly worse CSS than those with normal preoperative GNRIs. Similarly, there were significant differences in OS (Supplementary Figure 1). Additionally, multivariate analysis identified GNRI as an independent risk factor for CSS. The results obtained in this study are consistent with those shown in previous reports related to lung and gastric cancers \[[@R10]--[@R12]\].

The TNM staging is useful for predicting the survival in patients with different stages of cancer, but a precise prediction is often difficult among those with the same stage of cancer. Therefore, additional indicators are needed to distinguish different prognoses in the same TNM stage \[[@R16]\]. In this study, we focused on stage-stratified survival analysis with special attention to the GNRI in patients with ESCC. Multivariate analysis identified the GNRI as an independent predictor of CSS in patients with pTNM stage I ESCC. In patients with pTNM stage II ESCC, when compared to the normal GNRI, a low GNRI was associated with a significantly worse CSS in univariate analysis; no significant differences were noted among patients with pTNM stage III ESCC. These findings suggested that malnutrition could lead to worse CSS, even in patients with pTNM stage I and II ESCC after undergoing curative esophagectomy. The basic mechanism underlying the association between low GNRI and worse prognosis is unclear. From a nutritional perspective, patients with cancer tend to be malnourished and usually show a diminished anabolic response to nutritional repletion. Additionally, albumin synthesis may be suppressed even in patients with early stage cancers \[[@R17]\]. However, tumor-related factors may have a stronger impact than nutrition-related ones, on the prognoses in patients with advanced stages of cancer \[[@R18], [@R19]\]. The above-mentioned facts may explain why GNRI had no significant association with CSS in patients with pTNM stage III ESCC in our study. With tumor progression, tumor-related factors, such as invasion and migration, may gradually play a more prominent role in patient survival, when compared to nutrition-related factors \[[@R20]--[@R22]\].

Yamana *et al*. were the first to demonstrate that GNRIs can be a reliable predictor of OS in esophageal cancer patients and to report the clinical significance of GNRIs by preoperative treatment modality \[[@R23]\]. Subsequently, Migita *et al*. suggested that low preoperative GNRI was associated with a higher risk of cancer death in patients who underwent curative esophagectomy for esophageal cancer \[[@R24]\]. Wang also reported that GNRI was a predictive marker of OS and progression-free survival (PFS) in patients aged 70 years and older who have received radiation therapy or definitive concurrent chemoradiotherapy \[[@R25]\]. To the best of our knowledge, our study is the first report demonstrating that preoperative GNRI is an independent prognostic factor in patients with pTNM stage I ESCC and a significant prognostic marker in patients with pTNM stage II. Our results suggested that preoperative GNRI could be a useful marker to identify patients at high-risk for ESCC and that patients with pTNM stage I and II ESCC who have low GNRIs may require more careful follow-up even after undergoing curative esophagectomy.

Our study shows some limitations in confirming our findings. First, the present study cannot unambiguously determine the prognostic role of GNRI in ESCC patients because of its retrospective nature and small sample size. Second, nutritional and inflammatory assessments by parameters other than the GNRI were not conducted. Third, the GNRI was used as the only nutritional screening tool, and its utility was not compared with those of other common assessment tools, such as the assessment of prealbumin, sarcopenia, or the Glasgow prognostic scores (GPS). To overcome these limitations, further studies with a prospective nature and a more comprehensive design are warranted.

The survival outcomes in patients with ESCC after undergoing curative resection, even in those with earlier stages of ESCC, are insufficient when compared to those in patients with other malignancies \[[@R26]\]. The benefit of neoadjuvant and postoperative adjuvant chemotherapies for patients with pathological stage II or III ESCC has been established in Japan; the long-term outcomes are still unsatisfactory \[[@R27], [@R28]\]. More effective personalized treatment strategies for patients with ESCC should be established.

In conclusion, preoperative GNRI can be used to sort patients into groups at high- or low-risk for shorter CSS after undergoing curative resection for ESCC, especially those with pTNM stage I and II ESCC; the interpretation should be done with care due to the differences in clinical background. Therefore, multicenter prospective validation of our findings is considered necessary to confirm the usefulness of GNRI as clinical therapeutic stratification marker for patients requiring more aggressive multimodality treatment or stringing surveillance.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We retrospectively analyzed the prognostic significance of the GNRI in a total of 191 patients with ESCC who underwent curative esophagectomies, between January 2006 and October 2017, in our institute. All patients underwent thoracoscopic subtotal esophagectomies with three-field lymph node dissections, with elevation of the gastric conduit to the neck via the posterior mediastinal approach or the retrosternal approach with anastomosis of the cervical esophagus and the gastric conduit. Postoperative adjuvant and post-recurrence chemotherapy were administered according to the guidelines edited by the Japan Esophageal Society \[[@R29], [@R30]\]. According to the guidelines, preoperative chemotherapy is recommended as grade B. However, the patients who did not wish to undergo preoperative chemotherapy were preceded by surgical therapy because the current preoperative chemotherapy with 5FU and CDDP did not provide a prognostic benefit in Stage III patients. The inclusion criteria were specified as follows: 1) histologically confirmed ESCC; 2) no preoperative anticancer treatment; 3) no history of cancer or co-existence of another synchronous cancer; and 4) complete removal of ESCC without any microscopic resection margin involvement. A perioperative multidisciplinary management team including surgeons, dental hygienists, pharmacists, and nutritionists was formed to provide preoperative enteral nutrition to optimize the preoperative condition as much as possible, which aimed to reduce the incidence of postoperative complications. A blood sample used for the analysis was collected from each patient within one week before the surgery.

The study was approved by the Ethical Review Board of Shimane University Faculty of Medicine (Shimane, Japan). The requirement for informed consent was waived because of the retrospective nature of this cohort study.

Surveillance {#s4_2}
------------

Postoperative follow-up evaluations were performed every 3 months for the first 2 years after the surgery, and every 6 months from the 2nd to 5th year after surgery, or until the patient died. We calculated the CSS as the date from primary esophagectomy to death due to cancer-specific causes.

The GNRI {#s4_3}
--------

The GNRI comprised two nutritional indicators: serum albumin levels and measured body weight compared with ideal body weight. The formula of GNRI was as follows: GNRI = \[1.487 × serum albumin (g/L)\] + \[41.7 × measured/ideal body weight (BW) (kg)\]. Ideal BW (kg) = 22 × square of height (m^2^) \[[@R2]\]. The ratio of measured BW to ideal BW was set to 1 when the measured BW of the patient exceeded the ideal BW. The ability of the GNRI to predict the CSS was assessed using a receiver operating characteristic (ROC) curve analysis, wherein the most discriminative cutoff value of GNRI was set at 97.1 with an area under curve (AUC) value of 0.608 (sensitivity, 66.9%; specificity, 58.2%) in this study ([Figure 4](#F4){ref-type="fig"}). Patients were classified into two groups based on the cutoff value of GNRI as follows: the normal GNRI (GNRI ≥ 97.1) and low GNRI (GNRI \< 97.1) groups.

![ROC for cancer death was plotted to verify the optimum cutoff of GNRI.\
Abbreviation: ROC, receiver operating characteristic.](oncotarget-11-2834-g004){#F4}

Statistical analysis {#s4_4}
--------------------

The differences between the study groups were evaluated using the Chi-square test or Student's *t*-test for categorical variables. The Kruskal--Wallis analysis was performed for non-normally distributed continuous variables among the three groups. The CSS was calculated using the Kaplan--Meier method, and the difference between the survival curves was assessed using the log-rank test.

Variables with *p* \< 0.05 in the univariate analysis were subjected to multivariate logistic regression analysis using Cox proportional hazards model. All statistical analyses were performed using the JMP software (version 14 for Windows; SAS Institute), and statistical significance was set to *p* \< 0.05.

SUPPLEMENTARY MATERIALS {#s5}
=======================
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AUC

:   area under curve

BMI

:   Body Mass Index

CI

:   Confidence Interval

CRP

:   C-reactive protein

CSS

:   Cancer-specific survival

ESCC

:   Esophageal squamous cell carcinoma

GNRI

:   geriatric nutritional risk index

GPS

:   Glasgow prognostic score

HR

:   Hazard Ratio

OS

:   overall survival

pTNM

:   pathological tumor-node-metastasis

ROC

:   receiver operating characteristic

SCC

:   squamous cell carcinoma

WBC

:   white blood cell
